# Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Source: https://onco.cc/trials/nct06710132/  
OnCo record `nct06710132` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Precemtabart tocentecan in non-small-cell lung cancer and small-cell lung cancer, run by EMD Serono Research & Development Institute, Inc., active and no longer recruiting.

## Summary

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) is a phase 1/2 interventional study registered as NCT06710132 by EMD Serono Research & Development Institute, Inc., with 184 participants enrolled, started 2025-01-29 and due to reach its primary completion in 2027-12-23. Interventions recorded: M9140. Conditions listed: Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06710132
- Phase: 1/2
- Setting: PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)
- Sponsor: EMD Serono Research & Development Institute, Inc.
- Enrolled: 184

## Sources

- ClinicalTrials.gov NCT06710132: https://clinicaltrials.gov/study/NCT06710132

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Precemtabart tocentecan](https://onco.cc/drugs/precemtabart-tocentecan/)
- companies: [Merck KGaA (EMD Serono)](https://onco.cc/companies/merck-kgaa/)

---
JSON: https://onco.cc/api/v1/entities/nct06710132.json